Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Sanofi, Teva tout midstage win for TL1A antibody in Crohn’s, UC
As Merck and Roche march their IBD assets through the clinic, Sanofi and Teva are closing the gap with new data from their own anti-TL1A antibody.
Fraiser Kansteiner
Dec 17, 2024 10:30am
AbbVie acquires oral peptide biotech Nimble for $200M
Dec 13, 2024 10:38am
Biotechs behind J&J-bought Yellow Jersey partner on IBD drug
Nov 15, 2024 8:30am
Teva brings biotech ethos to drug development, exec says
Oct 15, 2024 4:33pm
Ensho emerges with phase 2-ready asset from Eisai unit
Jun 28, 2024 11:10am
AbbVie turns up the M&A heat with $250M Celsius buy
Jun 27, 2024 11:00am
